BBIO - BridgeBio Pharma GAAP EPS of -$0.95 misses by $0.06, revenue of $120.7M beats by $14.65M
2025-10-29 16:04:15 ET
More on BridgeBio Pharma
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study - Slideshow
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript
- BridgeBio succeeds in late-stage encaleret study
- BridgeBio Pharma Q3 2025 Earnings Preview